JOENJA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JOENJA (JOENJA).
JOENJA (lenvatinib) is a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. It blocks tumor angiogenesis and proliferation.
| Metabolism | Primarily metabolized by CYP3A4 and aldehyde oxidase (AO). Minor pathways include CYP3A5 and CYP2C8. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70-80% of the dose). A small fraction (5-10%) is eliminated via feces via biliary excretion. The remainder is metabolized and excreted as inactive metabolites. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function. This supports once-daily dosing in most indications. Half-life is prolonged in renal impairment, requiring dose adjustment. |
| Protein binding | Approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations and may be altered in disease states (e.g., hepatic impairment, hypoalbuminemia). |
| Volume of Distribution | Volume of distribution is approximately 0.6-0.8 L/kg, indicating distribution into total body water. This suggests extensive extravascular distribution, with higher concentrations in well-perfused organs (liver, kidneys) and lower in adipose tissue. |
| Bioavailability | Oral bioavailability is approximately 60-70%, with moderate interindividual variability. Food does not significantly affect absorption. No other relevant routes (e.g., topical) are available; bioavailability via IV is 100%. |
| Onset of Action | Oral administration: Clinical effect is observed within 1-2 hours. Intravenous administration: Onset within 15-30 minutes. Peak plasma concentrations occur at 2-3 hours (oral) and end of infusion (IV). |
| Duration of Action | Duration is approximately 24 hours following a single dose, consistent with once-daily dosing. Steady-state is achieved within 5-7 days. Continuous therapy maintains the effect; missed doses may result in loss of efficacy within 36-48 hours. |
JOENJA (lenalidomide) 2.5 mg orally once daily on days 1-21 of a 28-day cycle.
| Dosage form | TABLET |
| Renal impairment | For CrCl 30-60 mL/min: 2.5 mg orally once daily; for CrCl <30 mL/min (not on dialysis): 1.25 mg orally once daily; for ESRD on dialysis: 2.5 mg orally once daily, dose after dialysis. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years. |
| Geriatric use | No specific dose adjustment; monitor renal function and adjust dose based on CrCl. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JOENJA (JOENJA).
| Breastfeeding | Unknown if excreted in human milk. The M/P ratio has not been determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 1 month after last dose. |
| Teratogenic Risk | First trimester: Based on animal studies, there is evidence of teratogenicity including cardiovascular and neural tube defects. Human data are limited; however, the drug should be avoided in the first trimester unless benefits outweigh risks. Second/third trimester: May cause fetal growth restriction and oligohydramnios; use only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["None known"]
| Precautions | ["Hypertension (including hypertensive crisis)","Cardiac dysfunction (reduced LVEF)","Arterial thromboembolic events","Hepatic impairment (including hepatotoxicity)","Renal impairment (including proteinuria)","Hemorrhage","Gastrointestinal perforation or fistula","QT prolongation","Reversible posterior leukoencephalopathy syndrome (RPLS)","Thyroid dysfunction","Wound healing complications"] |
| Food/Dietary | Avoid grapefruit, grapefruit juice, and star fruit as they inhibit CYP3A4 and may increase lapatinib levels. Administer on an empty stomach; food, especially high-fat meals, can increase lapatinib AUC by 2-3 times and Cmax by 3-4 times, increasing toxicity risk. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and electrolytes monthly. Fetal monitoring includes ultrasound for growth and amniotic fluid volume every 4 weeks starting at 20 weeks gestation. Assess fetal heart rate tracing at each visit after 24 weeks. |
| Fertility Effects | In animal studies, JOENJA reduced fertility indices in both males and females at clinically relevant doses. Human data are unavailable; may impair spermatogenesis and oocyte maturation. Advise patients of potential reversible infertility. |
| Clinical Pearls | JOENJA (lapatinib) is a dual tyrosine kinase inhibitor of EGFR and HER2. Use with caution in patients with severe hepatic impairment (Child-Pugh C); reduce dose to 750 mg/day. Monitor for QT prolongation, especially in patients with hypokalemia or hypomagnesemia, or those on concurrent QT-prolonging drugs. Diarrhea is common (grades 1-2 in ~50%); premedicate with loperamide and ensure adequate hydration. Hepatotoxicity (ALT >5x ULN) occurs in ~2%; discontinue if severe. Avoid concurrent strong CYP3A4 inducers (e.g., rifampin) as they decrease lapatinib AUC by up to 70%. |
| Patient Advice | Take JOENJA on an empty stomach, at least 1 hour before or 1 hour after a meal; do not take with food as it increases absorption unpredictably. · Do not crush, chew, or split tablets; swallow whole. · If you miss a dose, take it as soon as you remember unless it is less than 12 hours before the next dose; then skip the missed dose. · Avoid grapefruit, grapefruit juice, and star fruit during treatment. · Use effective non-hormonal contraception during treatment and for at least 1 week after the last dose. · Report severe or persistent diarrhea, yellowing of skin or eyes, dark urine, or unusual bruising/bleeding to your healthcare provider. |